ORMDL2

Across TCGA pan-cancer cohorts, ORMDL2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ORMDL2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ORMDL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ORMDL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC and LSCC are the cancer types where ORMDL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.850	0.511	<.001	52	view →
LSCC	DFS	Tertile	All	0.879	0.689	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ORMDL2–HNSC (DFS)

Open the HNSC breakdown →